Emerging drugs for the treatment of ulcerative colitis

Expert Opinion on Emerging Drugs

Volumn 14, Issue 3, 2009, Pages 505-521

  Pastorelli, Luca ^a,b   Pizarro, Theresa T ^a   Cominelli, Fabio ^c   Vecchi, Maurizio ^b,d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Adhesion molecules; Biologic drugs; CD3; CTLA 4; IL 2 receptor; Inflammatory bowel disease; MMX; PPAR ; Probiotics; Therapy; TNF ; Treatment; Ulcerative colitis

Indexed keywords

ABATACEPT; ADALIMUMAB; ALICAFORSEN; AZATHIOPRINE; BASILIXIMAB; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CYCLOSPORIN A; DERSALAZINE; EPIDERMAL GROWTH FACTOR; GASTROINTESTINAL AGENT; GOLIMUMAB; INFLIXIMAB; KAPPAPROCT; MERCAPTOPURINE; MESALAZINE; MONOCLONAL ANTIBODY; NATALIZUMAB; PARNAPARIN; PHOSPHATIDYLCHOLINE; PLACEBO; PROBIOTIC AGENT; ROSIGLITAZONE; SALAZOSULFAPYRIDINE; STEROID; TRAFICET EN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOLIZUMAB; VISILIZUMAB; VSL3;

ACUTE PANCREATITIS; ADRENAL INSUFFICIENCY; ANGIONEUROTIC EDEMA; BIOLOGICAL THERAPY; BLOOD DISEASE; CARDIOVASCULAR DISEASE; CATARACT; CELIAC DISEASE; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CROHN DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENTERITIS; GINGIVA HYPERPLASIA; GLAUCOMA; HEART DISEASE; HELMINTH; HEPATITIS; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ILEITIS; INFECTION; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; LEUKAPHERESIS; LEUKOPENIA; LYMPHOMA; MAINTENANCE THERAPY; MULTIPLE SCLEROSIS; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PANCREATITIS; PATHOGENESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SKIN FRAGILITY; TABLET MATRIX; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULAR DISEASE;

ANTI-INFLAMMATORY AGENTS; BIOLOGICAL PRODUCTS; CHEMISTRY, PHARMACEUTICAL; COLITIS, ULCERATIVE; DRUG DISCOVERY; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; PPAR GAMMA; PROBIOTICS;

EID: 69949126456     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210903146882     Document Type: Review

References (119)

1. Vecchi M, Saibeni S, Devani M, et al. Review article: diagnosis, monitoring and treatment of distal colitis. Aliment Pharmacol Ther 2003;17(Suppl 2):2-6 (Pubitemid 36831451)
2. Hoie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol 2007;102(8):1692-1701 (Pubitemid 47206689)
3. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107(1):3-11 (Pubitemid 24195339)
4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48(4):526-535 (Pubitemid 32234798)
5. Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol 2008;14(25):3937-3947
6. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008;14(4):554-565 (Pubitemid 351571837)
7. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003;98(5):1064-1072 (Pubitemid 36733768)
8. Bebb JR, Scott BB. How effective are the usual treatments for ulcerative colitis? Aliment Pharmacol Ther 2004;20(2):143-149
9. D'Inca R, Bertomoro P, Mazzocco K, et al. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008;27(2):166-172 (Pubitemid 350256604)
10. Cerveny P, Bortlik M, Kubena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007;13(10):1244-1249 (Pubitemid 47597771)
11. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;(2):CD000544
12. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107(1):117-120 (Pubitemid 24195353)
13. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14(2):145-153 (Pubitemid 30088290)
14. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8(12):1179-1183 (Pubitemid 26413548)
15. Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am 2004;33(2):303-17, ix-x
16. Gionchetti P, Ardizzone S, Benvenuti ME, et al. A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment Pharmacol Ther 1999;13(3):381-388 (Pubitemid 29142048)
17. Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn's disease: a controlled trial. Gut 1978;19(7):606-610 (Pubitemid 8388152)
18. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130(3):940-987 (Pubitemid 43374543)
19. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121(2):255-260 (Pubitemid 32729372)
20. Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17(12):1471-1480 (Pubitemid 36831438)
21. Gionchetti P, D'Arienzo A, Rizzello F, et al. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. J Clin Gastroenterol 2005;39(4):291-297 (Pubitemid 40393243)
22. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98(4):811-818
23. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006;24(5):715-729 (Pubitemid 44244896)
24. Saibeni S, Virgilio T, D'Inca R, et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis 2008;40(10):814-820
25. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(1):CD000478 (Pubitemid 351820399)
26. Jones JL, Loftus EV. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007;13(10):1299-1307
27. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54(8):1121-1125 (Pubitemid 41025906)
28. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330(26):1841-1845 (Pubitemid 24188135)
29. Poritz LS, Rowe WA, Swenson BR, et al. Intravenous cyclosporine for the treatment of severe steroid refractory ulcerative colitis: what is the cost? Dis Colon Rectum 2005;48(9):1685-1690
30. Rayner CK, McCormack G, Emmanuel AV, Kamm MA. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther 2003;18(3):303-308 (Pubitemid 37046709)
31. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-2476 (Pubitemid 41770166)
32. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128(7):1805-1811 (Pubitemid 40824691)
33. Lin J, Ziring D, Desai S, et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126(1):13-30 (Pubitemid 350266448)
34. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124(4):917-924 (Pubitemid 36389794)
35. Sawada K, Muto T, Shimoyama T, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003;9(4):307-321 (Pubitemid 36131725)
36. Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100(6):1362-1369 (Pubitemid 40904363)
37. Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004;70(1):36-44 (Pubitemid 39179238)
38. Kruis W, Dignass A, Steinhagen-Thiessen E, et al. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005;11(44):7001-7006 (Pubitemid 43126060)
39. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135(2):400-409
40. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008;14(3):401-407 (Pubitemid 351320848)
41. D'Inca R, Annese V, di Leo V, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment Pharmacol Ther 2006;23(10):1455-1461
42. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005;102(50):18129-18134 (Pubitemid 41798513)
43. Tannock GW. Molecular analysis of the intestinal microflora in IBD. Mucosal Immunol 2008;1(Suppl 1):S15-8
44. Coffey JC, Rowan F, Burke J, et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol 2009;104(4):1013-1023
45. Edmond LM, Hopkins MJ, Magee EA, Cummings JH. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria. Inflamm Bowel Dis 2003;9(1):10-17
46. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146(12):829-838 (Pubitemid 351650483)
47. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13(16):2328-2332 (Pubitemid 46860734)
48. Oussalah A, Laclotte C, Chevaux JB, et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28(8):966-972
49. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009 [Epub ahead of print]
50. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to TNF-{alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: the GO-FORWARD Study. Ann Rheum Dis 2009;68(6):789-796
51. Creed TJ, Norman MR, Probert CS, et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 2003;18(1):65-75
52. Creed TJ, Probert CS, Norman MN, et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006;23(10):1435-1442
53. Monteleone G, Boirivant M, Pallone F, MacDonald TT. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol 2008;1(Suppl 1):S50-3
54. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 2006;131(6):1786-1798 (Pubitemid 44958514)
55. Wehkamp J, Harder J, Wehkamp K, et al. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004;72(10):5750-5758
56. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007;446(7135):557-561 (Pubitemid 46514732)
57. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289(5483):1352-1355 (Pubitemid 30656052)
58. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4(6):754-759 (Pubitemid 43841860)
59. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs R D 2004;5(2):102-107 (Pubitemid 38607632)
60. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-1925 (Pubitemid 41565956)
61. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16(4):699-705 (Pubitemid 34407517)
62. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353(4):362-368 (Pubitemid 41132340)
63. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005;352(24):2499-2507
64. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51(1):30-36 (Pubitemid 34717740)
65. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004;53(11):1646-1651
66. Yu QT, Saruta M, Papadakis KA. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol 2008;127(3):322-329
67. Plevy S, Salzberg B, Van Assche G, et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 2007;133(5):1414-1422 (Pubitemid 350029746)
68. Sandborn W, Colombel JF, Frankel M, et al. A Placebo-Controlled Trial of Visilizumab in Patients with Intravenous (IV) Steroid Refractory Ulcerative Colitis (UC). Digestive Disease Week; 2009; Chicago; 2009
69. Dall'Era M, Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus 2004;13(5):372-376
70. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009 [Epub ahead of print]
71. Schiff MH, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2008 [Epub ahead of print]
72. Lefebvre M, Paulweber B, Fajas L, et al. Peroxisome proliferator- activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 1999;162(3):331-340 (Pubitemid 29447426)
73. Spiegelman BM. PPARgamma in monocytes: less pain, any gain? Cell 1998;93(2):153-155
74. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93(2):241-252 (Pubitemid 28180857)
75. Fajas L, Debril MB, Auwerx J. PPAR gamma: an essential role in metabolic control. Nutr Metab Cardiovasc Dis 2001;11(1):64-69 (Pubitemid 33687794)
76. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005;201(8):1205-1215 (Pubitemid 40629065)
77. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006;55(9):1341-1349 (Pubitemid 44277368)
78. Sanchez-Hidalgo M, Martin AR, Villegas I, et al. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 2005;69(12):1733-1744 (Pubitemid 40780073)
79. Sanchez-Hidalgo M, Martin AR, Villegas I, et al. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur J Pharmacol 2007;562(3):247-258 (Pubitemid 46560498)
80. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 2008;134(3):688-695 (Pubitemid 351312727)
81. Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 2008;14(1):114-119 (Pubitemid 351314337)
82. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298(10):1189-1195 (Pubitemid 47403105)
83. Ehehalt R, Wagenblast J, Erben G, et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol 2004;39(8):737-742 (Pubitemid 39093247)
84. Stremmel W, Merle U, Zahn A, et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54(7):966-971 (Pubitemid 40873911)
85. Stremmel W, Ehehalt R, Autschbach F, Karner M. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007;147(9):603-610 (Pubitemid 351664479)
86. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003;349(4):350-357 (Pubitemid 36886241)
87. Pagnini C, Cominelli F. Probiotics in experimental and human inflammatory bowel disease: discussion points. Dig Liver Dis 2006;38(Suppl 2):S270-3 (Pubitemid 46140767)
88. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 2008;14(11):1585-1596
89. Mondel M, Schroeder BO, Zimmermann K, et al. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2009;2(2):166-172
90. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11(5):853-858 (Pubitemid 27445670)
91. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53(11):1617-1623
92. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354(9179):635-639 (Pubitemid 29391428)
93. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005;100(7):1539-1546 (Pubitemid 41032360)
94. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13(8):1103-1108 (Pubitemid 29374113)
95. Huynh HQ, Debruyn J, Guan L, et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 2009;15(5):760-768
96. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 2009;104(2):437-443
97. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003;15(6):697-698 (Pubitemid 36688235)
98. Ishikawa H, Akedo I, Umesaki Y, et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003;22(1):56-63 (Pubitemid 36164458)
99. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;(4):CD005573 (Pubitemid 351805347)
100. Elliott DE, Summers RW, Weinstock JV. Helminths as governors of immune-mediated inflammation. Int J Parasitol 2007;37(5):457-464
101. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy in Crohn's disease. Gut 2005;54(1):87-90 (Pubitemid 40007223)
102. Summers RW, Elliott DE, Urban JF, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 2005;128(4):825-832 (Pubitemid 40523535)
103. Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003;17(3):395-402 (Pubitemid 36259402)
104. Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 2006;61(1):31-38 (Pubitemid 43381235)
105. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005;11(5):421-427 (Pubitemid 40704075)
106. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007;132(1):66-75; quiz 432-433 (Pubitemid 46108735)
107. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5(1):95-102 (Pubitemid 46096842)
108. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57(7):893-902
109. D'Haens GR, Kovács á, Vergauwe P, et al. Safety and efficacy of a novel extended release budesonide formulation in patients with active left sided ulcerative colitis. Gastroenterology 2007;132(Suppl 2):T1276
110. Watts P, Smith A. TARGIT technology: coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract. Expert Opin Drug Deliv 2005;2(1):159-167 (Pubitemid 40123890)
111. Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007;33(5):524-533
112. Celasco G, Moro L, Bozzella R, et al. Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci 2008;53(12):3170-3175
113. Pastorelli L, Saibeni S, Spina L, et al. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2008;28(5):581-588
114. Magnani M, Rossi L, D'Ascenzo M, et al. Erythrocyte engineering for drug delivery and targeting. Biotechnol Appl Biochem 1998;28(Pt 1):1-6 (Pubitemid 28369899)
115. Pierige F, Serafini S, Rossi L, Magnani M. Cell-based drug delivery. Adv Drug Deliv Rev 2008;60(2):286-295
116. Annese V, Latiano A, Rossi L, et al. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients-a pilot uncontrolled study. Am J Gastroenterol 2005;100(6):1370-1375 (Pubitemid 40904364)
117. Bossa F, Latiano A, Rossi L, et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 2008;103(10):2509-2516
118. Galvez J, Garrido M, Rodriguez-Cabezas ME, et al. The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. Inflamm Bowel Dis 2003;9(6):363-371 (Pubitemid 37461447)
119. Auci D, Kaler L, Subramanian S, et al. A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells. Ann NY Acad Sci 2007;1110:630-640 (Pubitemid 350043052)